Q2 2025 Medexus Pharmaceuticals Inc Earnings Call Transcript
Key Points
- Medexus Pharmaceuticals Inc (MEDXF) reported its 10th consecutive quarter of positive operating income and 12th consecutive quarter of positive adjusted EBITA, demonstrating strong commercial execution.
- The company achieved a $6 million adjusted EBITA from $26.3 million in revenue, reflecting successful cost management and financial discipline.
- Rupall unit demand in Canada increased by 17% over the trailing 12-month period, contributing significantly to revenue.
- Treosulfan is expected to have a material positive impact on total revenue, with potential annual product-level revenue in the United States exceeding $100 million within five years post-launch.
- Medexus Pharmaceuticals Inc (MEDXF) has begun preparations for the potential approval of Treosulfan by the end of January 2025, including investments in personnel and infrastructure.
- Fiscal Q2 2025 revenue decreased to $26.3 million from $30.3 million in the same period last year, primarily due to reduced net sales of Rasuvo and declines in Ixinity sales.
- Operating income decreased to $1.6 million, down from $3.6 million in the same period last year.
- Ixinity unit demand in the United States decreased by 4% over the trailing 12-month period, posing a challenge to maintaining existing demand.
- Rupall is expected to face generic competition in early 2025, which may impact its revenue contribution.
- The company has $17.8 million of current debt, raising concerns about its ability to service this debt in the upcoming year.
Good morning, everyone and welcome to the Medexus Pharmaceuticals second quarter, 2025 conference call at this time. All participants are in a listen-only mode and we will open for questions following the presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. Please note this conference is being recorded. I will now turn the conference over to your host, Victoria Rutherford Investor Relations. Victoria, the floor is yours.
Thank you and good morning, everyone. Welcome to the Medexus Pharmaceuticals second fiscal quarter 2025 earnings call on the call this morning are Ken D'entermont, Chief Executive Officer and Brendon Buschman, Chief Financial Officer. If you have any questions after the call or would like further information about the company, please contact Adelaide Capital at 4806255772. I would like to remind everyone that this discussion will include forward-looking information as defined in securities laws.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
